In 2012, researchers determined a considerable added benefit for ipilimumab in pretreated patients. However, there were no suitable data for non-pretreated patients. Since the treatment effects presented by the manufacturer were not interpretable, an added benefit of ipilimumab in non-pretreated patients with advanced melanoma is not proven.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/_...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/_...